附件99.3
討論和
非盈利者的和解
GAAP財務指標
2024年9月30日
(未經審計)
| 定義 | ||
調整後固定費用覆蓋率 按照固定費用覆蓋調整後的EBITDAre除以固定費用計算得出。調整後的固定費用覆蓋是流動性的補充指標，反映我們支付利息及分紅給優先股東（如適用）的能力。我們的各項債務協議包含要求我們維持類似調整後的固定費用覆蓋比率的契約，信用評級機構在評估和確定我們某些債券的信用評級時也會使用類似的比率。調整後的固定費用覆蓋受到調整後的EBITDAre和固定費用的相同限制和條件的約束。
調整後的基金來自運營（「AFFO」） AFFO被定義爲FFO在調整後排除以下影響：(i)基於股票的補償攤銷費用，(ii) 專項融資費用和債務折扣（溢價）的攤銷，(iii) 直線租金，(iv) 推遲所得稅，(v) 淨額上下市場租賃無形資產的攤銷，以及(vi)其他AFFO調整，包括：(a) 租賃激勵攤銷（減少直線租金），(b) 針對已發生但未報告的保險賠償的精算準備金，和(c) 推遲收入的攤銷，不包括攤入租金收入的金額，這些金額與租客資助的由我們擁有/確認的改進和租客預付款相對應。此外，AFFO在扣除定期資本支出後計算，包括第二代租賃費用和第二代租戶及資本改進（「AFFO資本支出」）。所有調整反映了我們對合資企業（報告在「其他AFFO調整」中）的比例份額的實質份額和非實質份額。我們通過將適用期間的實際所有權百分比應用於按實體方式歸類的相應調整項目，反映了我們對非合併合資企業的AFFO份額。對於我們不擁有100%股權的合併合資企業，我們通過根據適用期間的實際所有權百分比調整我們的AFFO，以排除適用期間的第三方所有權份額的調整項目。有關我們使用按比例份額信息及其侷限性的進一步披露，請參見下文的「Nareit FFO」。我們認爲AFFO是一種改善投資者對我們運營結果的理解、使期望結果、以往期間結果和與REITs間結果比較更有意義的替代性經常性盈利度量。AFFO不代表根據GAAP確定的經營活動產生的現金，不表示可用於資金需求的現金，因爲它排除了通常流經我們從經營活動產生的現金流的以下項目：(i) 爲期間應計的收入或費用項目的變動進行調整，(ii) 與交易相關的成本，(iii) 訴訟和解決費用，以及(iv) 重組和與解聘相關的費用。此外，AFFO還針對通常在確定經營活動現金流或流動性時不予考慮的定期資本支出進行調整。其他REITs或房地產公司可能使用不同的計算AFFO的方法，因此，我們的AFFO可能與其他REIT報告的不可比。管理層認爲AFFO是我們績效的一個有意義的補充衡量標準，經常被分析師，投資者和其他利益相關方在評估我們作爲REIT的表現時使用，通過提供AFFO，我們正在協助這些利益相關方進行評估。AFFO是一項非GAAP的補充財務指標，不應被視爲根據GAAP確定的淨收入（損失）的替代，只有與我們按照GAAP準備的財務信息一起並作爲補充考慮時才應被視爲。
調整後的淨營業收入和現金（調整後）淨營業收入（"NOI"） 調整後的淨營業收入是一項非美國通用會計準則（"GAAP"）的附加財務指標，用於評估房地產的經營績效。調整後的淨營業收入定義爲房地產收入（包括租金和相關收入、居民費用和服務費用以及政府補助收入，不包括利息收入），減去物業級別的營業費用；調整後的淨營業收入不包括淨利潤（虧損）中包括的所有其他財務報表金額。 調整後的淨營業收入消除了直線租金、攤銷市場租賃無形資產、終止費用、已發生但未報告的保險賠款的精算準備，以及延期社區費用收入和費用的影響。調整後的淨營業收入是從合併物業的調整後淨營業收入計算得出，再加上我們在非合併聯營企業中的調整後淨營業收入份額（根據所需期間應用我們實際持股比例計算），減去非控股權益在合併聯營企業的調整後淨營業收入份額（根據我們實際持股比例計算）。我們在評估自身績效時利用我們的調整後淨營業收入份額，因爲我們有多個聯營企業 contributing to our performance。我們無法控制非合併聯營企業，我們從非合併聯營企業獲得的金額不代表我們針對這些項目的法律索賠。我們的調整後淨營業收入份額不應被視爲美國通用會計準則所要求的財務信息的替代，只能與我們根據GAAP呈報的財務信息一起或作爲補充考慮。
調整後的淨營業收入通常被稱爲「現金淨營業收入」。管理層認爲調整後的淨營業收入是一項重要的補充指標，因爲它通過僅反映在物業級別發生的收入和運營費用項目，並以不負債的基礎呈現它們，提供相關且有用的信息。我們使用調整後的淨營業收入來做出關於資源配置的決策，評估和比較物業級別的表現，並評估我們的合併後相同店鋪（「合併後SS」）的表現，如下所述。我們相信淨利潤（損失）是與調整後的淨營業收入最直接可比的美國通用會計準則衡量標準。由於它不反映各種被排除項，調整後的淨營業收入不應被視爲淨利潤（損失）的替代經營績效指標。此外，我們對調整後的淨營業收入的定義可能不可與其他信託或房地產公司使用的定義相比較，因爲它們可能使用不同的計算方法來計算調整後的淨營業收入。
營業費用通常與租賃的門診醫療和實驗室建築以及CCRC設施有關。我們通常通過租戶收回來彌補全部或部分門診醫療和實驗室物業費用，這些費用在租金和相關收入中得到確認。
合併債務報告於我們的綜合基本報表中的銀行信用額度、商業票據、定期貸款、高級無擔保票據及抵押貸款的賬面價值。
合併總資產在加回積壓折舊及攤銷後，我們合併基本報表中報告的資產總額，不包括對我們非合併合資企業的投資和預付款項。合併總資產是我們財務狀況的一個補充指標，與債務相關的指標一起使用，使管理層和投資者能夠分析我們的槓桿情況，並將我們的槓桿情況與其他公司進行比較。
綜合抵押債務 按揭及其他由房地產業擔保的債務，根據我們的綜合基本報表所報告。
繼續護理養老社區（CCRC） 一個為老年人提供至少三個護理層次的住所（即獨立生活、輔助生活和熟練護理）的設施。
債務投資 貸款以房地產直接擔保和梅札南貸款。
| 2 | ||||
| 定義 | ||
發展 包括從頭開始的施工。一旦物業投入使用，新完成的開發項目被視為完全運作。
EBITDAre, Adjusted EBITDAre, and Fixed Charge Coverage Adjusted EBITDAre EBITDAre, or EBITDA for Real Estate, is a supplemental performance measure defined by the National Association of Real Estate Investment Trusts (“Nareit”) and intended for real estate companies. It represents earnings before interest expense, income taxes, depreciation and amortization, gains or losses from sales of depreciable property (including gains or losses on change in control), and impairment charges (recoveries) related to depreciable property. Adjusted EBITDAre is defined as EBITDAre excluding other impairments (recoveries) and other losses (gains), transaction and merger-related items, prepayment costs (benefits) associated with early retirement or payment of debt, restructuring and severance-related charges, litigation costs (recoveries), casualty-related charges (recoveries), stock-based compensation amortization expense, and foreign currency remeasurement losses (gains), adjusted to reflect the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period. Fixed Charge Coverage Adjusted EBITDAre is defined as Adjusted EBITDAre excluding the adjustment to reflect the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period. EBITDAre, Adjusted EBITDAre, and Fixed Charge Coverage Adjusted EBITDAre include our pro rata share of our unconsolidated JVs presented on the same basis. We consider EBITDAre and Adjusted EBITDAre important supplemental measures to net income (loss) because they provide an additional manner in which to evaluate our operating performance and serve as additional indicators of our ability to service our debt obligations. Net income (loss) is the most directly comparable U.S. generally accepted accounting principles (“GAAP”) measure to EBITDAre and Adjusted EBITDAre.
Enterprise Debt Consolidated Debt plus our pro rata share of total debt from our unconsolidated JVs. Enterprise Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Enterprise Gross Assets Consolidated Gross Assets plus our pro rata share of total gross assets from our unconsolidated JVs, after adding back accumulated depreciation and amortization. Enterprise Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.
Enterprise Secured Debt Consolidated Secured Debt plus our pro rata share of mortgage debt from our unconsolidated JVs. Enterprise Secured Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of Enterprise Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Entrance Fees Certain of our CCRC communities have residency agreements which require the resident to pay an upfront entrance fee prior to taking occupancy at the community. For net income, NOI, Adjusted NOI, Nareit FFO, FFO as Adjusted, and AFFO, the non-refundable portion of the entrance fee is recorded as deferred entrance fee revenue and amortized over the estimated stay of the resident based on an actuarial valuation. The refundable portion of a resident’s entrance fee is generally refundable within a certain number of months or days following contract termination or upon the sale of the unit. All refundable amounts due to residents at any time in the future are classified as liabilities.
Financial Leverage Enterprise Debt divided by Enterprise Gross Assets. Financial Leverage is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Fixed Charges Total interest expense plus capitalized interest plus preferred stock dividends (if applicable). Fixed Charges also includes our pro rata share of the interest expense plus capitalized interest plus preferred stock dividends (if applicable) of our unconsolidated JVs. Fixed Charges is a supplemental measure of our interest payments on outstanding debt and dividends to preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. Fixed Charges is subject to limitations and qualifications, as, among other things, it does not include all contractual obligations.
Funds From Operations (“Nareit FFO”) and FFO as Adjusted Nareit FFO. Funds from Operations (“FFO”), as defined by the National Association of Real Estate Investment Trusts (“Nareit”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO from joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of Nareit FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our Nareit FFO to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro rata presentations of reconciling items included in Nareit FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
The presentation of pro rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro rata financial information as a supplement.
| 3 | ||||
| Definitions | ||
We believe Nareit FFO applicable to common shares and diluted FFO applicable to common shares are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term Nareit FFO was designed by the REIT industry to address this issue.
Nareit FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute Nareit FFO in accordance with the current Nareit definition; however, other REITs may report Nareit FFO differently or have a different interpretation of the current Nareit definition from ours. For a reconciliation of net income (loss) to Nareit FFO and other relevant disclosures, refer to “Non-GAAP Financial Measures Reconciliations” below.
FFO as Adjusted. In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction and merger-related items, other impairments (recoveries) and other losses (gains), restructuring and severance-related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”). These adjustments are net of tax, when applicable, and are reflective of our share from our joint ventures. Adjustments for joint ventures are calculated to reflect our pro rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FFO as Adjusted for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO as Adjusted to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. See “Nareit FFO” above for further disclosures regarding our use of pro rata share information and its limitations. Transaction and merger-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including goodwill, undeveloped land parcels, and loans receivable. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that Nareit created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the Nareit defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs.
Investment and Portfolio Investment Represents: (i) the carrying amount of real estate assets and intangibles, after adding back accumulated depreciation and amortization and (ii) the carrying amount of Debt Investments. Portfolio Investment also includes our pro rata share of the real estate assets and intangibles held in our unconsolidated JVs, presented on the same basis as Investment, and excludes noncontrolling interests' pro rata share of the real estate assets and intangibles held in our consolidated JVs, presented on the same basis. Investment and Portfolio Investment include land held for development.
Merger-Combined Same-Store (“SS”) Merger-Combined Same-Store Cash (Adjusted) NOI includes legacy Physicians Realty Trust properties that met the same-store criteria as if they were owned by the Company for the full analysis period. This information allows our investors, analysts, and Company management to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in Merger-Combined Same-Store Adjusted NOI (see Cash (Adjusted) NOI definitions above for further discussion regarding our use of pro-rata share information and its limitations). Properties are included in Merger-Combined Same-Store once they are fully operating for the entirety of the comparative periods presented. A property is removed from Merger-Combined Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, or a significant tenant relocates from a Merger-Combined Same-Store property to a Merger-Combined non Same-Store property and that change results in a corresponding increase in revenue. We do not report Merger-Combined Same-Store metrics for our other non-reportable segments.
Management believes that continued reporting of the same-store portfolio for only pre-merger Healthpeak Properties, Inc. offers minimal value to investors who are seeking to understand the operating performance and growth potential of the combined company. The Company was provided access to the underlying financial statements of legacy Physicians Realty Trust (which financial statements have been audited or, in the case of interim periods, reviewed) and other detailed information about each property, such as the acquisition date. Based on this available information, the Company was able to consistently apply its same-store definition across the combined portfolio. As a result of the Merger, approximately 98% of the combined portfolio is represented in the Merger-Combined Same-Store presentation for the outpatient medical segment.
Merger-Combined Same-Store Cash (Adjusted) NOI Merger-Combined Same-Store Cash (Adjusted) NOI is Merger-Combined Same-Store Cash Real Estate Revenues less Merger-Combined Same-Store Cash Operating Expenses.
Merger-Combined Same-Store Cash Operating Expenses Merger-Combined Same-Store Cash Operating Expenses are non-GAAP supplemental measures. Merger-Combined Same-Store Cash Operating Expenses represent property level operating expenses (which exclude transition costs) and exclude certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis. Merger-Combined Same-Store Cash Operating Expenses include consolidated operating expenses plus the Company's pro rata share of
| 4 | ||||
| Definitions | ||
operating expenses from its unconsolidated JVs less noncontrolling interests' pro rata share of operating expenses from consolidated JVs. Merger-Combined Same-Store Cash Operating Expenses eliminates the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense.
Merger-Combined Same-Store Cash Real Estate Revenues Merger-Combined Same-Store Cash Real Estate Revenues are non-GAAP supplemental measures. Merger-Combined Same-Store Cash Real Estate Revenues include rental related revenues, resident fees and services and exclude amortization of deferred revenue from tenant-funded improvements. Merger-Combined Same-Store Cash Real Estate Revenues include the Company's pro rata share from unconsolidated JVs presented on the same basis and exclude noncontrolling interests' pro rata share from consolidated JVs presented on the same basis. Merger-Combined Same-store Cash Real Estate Revenues eliminates the effects of straight-line rents, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income.
Net Debt Enterprise Debt less the carrying amount of cash and cash equivalents, restricted cash, and expected net proceeds from the future settlement of shares issued through our equity forward contracts, as reported in our consolidated financial statements and our pro rata share of cash and cash equivalents and restricted cash from our unconsolidated JVs. Consolidated Debt is the most directly comparable GAAP measure to Net Debt. Net Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.
Net Debt to Adjusted EBITDAre Net Debt divided by Adjusted EBITDAre is a supplemental measure of our ability to decrease our debt. Because we may not be able to use our cash to reduce our debt on a dollar-for-dollar basis, this measure may have material limitations.
Portfolio Adjusted NOI Portfolio Adjusted NOI is Portfolio Cash Real Estate Revenues less Portfolio Cash Operating Expenses.
Portfolio Cash Operating Expenses Portfolio Cash Operating Expenses are non-GAAP supplemental measures. Portfolio Cash Operating Expenses represent property level operating expenses (which exclude transition costs). Portfolio Cash Operating Expenses include consolidated operating expenses plus the Company's pro rata share of operating expenses from its unconsolidated JVs less noncontrolling interests' pro rata share of operating expenses from consolidated JVs. Portfolio Cash Operating Expenses eliminates the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense.
Portfolio Cash Real Estate Revenues Portfolio Cash Real Estate Revenues are non-GAAP supplemental measures. Portfolio Cash Real Estate Revenues include rental related revenues, resident fees and services, and government grant income which is included in Other income (expense), net in our Consolidated Statement of Operations. Portfolio Cash Real Estate Revenues include the Company's pro rata share from unconsolidated JVs presented on the same basis and exclude noncontrolling interests' pro rata share from consolidated JVs presented on the same basis. Portfolio Cash Real Estate Revenues eliminates the effects of straight-line rents, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income.
Portfolio Income Cash (Adjusted) NOI plus interest income plus our pro rata share of Cash (Adjusted) NOI from our unconsolidated JVs less noncontrolling interests' pro rata share of Cash (Adjusted) NOI from consolidated JVs. Management believes that Portfolio Income is an important supplemental measure because it provides relevant and useful information regarding our performance; specifically, it is a measure of our property level profitability of the Company inclusive of interest income. Management believes that net income (loss) is the most directly comparable GAAP measure to Portfolio Income. Portfolio Income should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items.
Projected Stabilized Cash Yield Projected Cash (Adjusted) NOI at stabilization divided by the expected total development costs. Management considers Projected Stabilized Yield a useful metric for investors as it helps provide context to the expected effects that development projects will have on the Company’s future performance once stabilized.
Redevelopment Properties that incur major capital expenditures to significantly improve, change the use, or reposition the property pursuant to a formal redevelopment plan. Newly completed redevelopments, are considered fully operating once the property is placed in service. Redevelopment costs include only the incremental costs for the project.
REVPOR The 3-month average Cash Real Estate Revenues per occupied unit for the most recent period available. REVPOR excludes newly completed assets under lease-up, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR cannot be derived from the information presented for the Other portfolio as units reflect 100% of the unit capacities for unconsolidated JVs and revenue is at the Company's pro rata share. All facility occupancy data was derived solely from information provided by operators without independent verification by us. REVPOR relates to our Other non-reportable segment. REVPOR is a metric used to evaluate the revenue-generating capacity and profit potential of our other assets independent of fluctuating occupancy rates. It is also used in comparison against industry and competitor statistics, if known, to evaluate the quality of our other assets.
REVPOR CCRC The 3-month average Cash Real Estate Revenues per occupied unit excluding Cash NREFs for the most recent period available. REVPOR CCRC excludes newly completed assets under lease-up, assets sold, or acquired during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. All facility occupancy data was derived solely from information provided by operators without independent verification by us. REVPOR CCRC is a metric used to evaluate the revenue-generating capacity and profit potential of our CCRC assets independent of fluctuating occupancy rates. It is also used in comparison against industry and competitor statistics, if known, to evaluate the quality of our CCRC assets.
RIDEA A structure whereby a taxable REIT subsidiary is permitted to rent a healthcare facility from its parent REIT and hire an independent contractor to operate the facility.
Secured Debt Ratio Enterprise Secured Debt divided by Enterprise Gross Assets. Secured Debt Ratio is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of Total Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
| 5 | ||||
| Definitions | ||
Segments The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) outpatient medical; (ii) lab; and (iii) continuing care retirement community (“CCRC”).
聯營企業（"合資企業"）的份額 非控股權的按比例份額信息是通過應用非控股權在期間的實際持有百分比而編制的，旨在反映非控股權在我們投資組合中資產的財務狀況和經營業績中的比例經濟利益。
非合併合資企業（"JVs"）的份額 我們的比例份額信息是通過應用我們在該期間的實際持股百分比來準備的，旨在反映我們在投資組合中物業的財務狀況和運營結果中的比例經濟利益。對於租賃信息不可用的情況，將排除某些非合併合資企業的租賃統計。
| 6 | ||||
| 協調 | ||
| 所有基金類型資金運營資產 | ||
以千爲單位，每股數據除外
| 三個月之內結束 2020年9月30日 | 九個月結束 2020年9月30日 | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| 適用於普通股的淨收益（虧損） | $ | 85,675 | $ | 64,048 | $ | 237,985 | $ | 233,497 | |||||||||||||||
| 房地產業相關的折舊和攤銷 | 280,019 | 184,559 | 782,736 | 561,357 | |||||||||||||||||||
| Healthpeak在未納入合併範圍的合資企業中房地產相關的折舊和攤銷 | 12,127 | 6,190 | 32,520 | 18,076 | |||||||||||||||||||
| 非控股股權對房地產相關的折舊和攤銷的份額 | (4,534) | (4,571) | (13,705) | (14,042) | |||||||||||||||||||
| 房地產業折舊房地產的出售損益淨額 | (62,325) | — | (187,624) | (86,463) | |||||||||||||||||||
| 非控股權益在房地產業折舊房地產的出售損益中的份額 | — | — | — | 11,546 | |||||||||||||||||||
控制權變更的損益淨額(1) | 430 | — | (77,548) | (234) | |||||||||||||||||||
與房地產處置相關的稅款(2) | (145) | — | 11,512 | — | |||||||||||||||||||
| 適用於普通股的Nareit FFO | 311,247 | 250,226 | 785,876 | 723,737 | |||||||||||||||||||
| 拆分稀釋可轉換單位和其他支付 | 4,577 | 2,340 | 11,670 | 7,027 | |||||||||||||||||||
| 適用於普通股的稀釋後Nareit FFO | $ | 315,824 | $ | 252,566 | $ | 797,546 | $ | 730,764 | |||||||||||||||
| 加權平均流通股數 - 稀釋後Nareit FFO | 714,715 | 554,614 | 681,128 | 554,535 | |||||||||||||||||||
| 對Nareit FFO調整的影響: | |||||||||||||||||||||||
交易和併購相關項目(3) | $ | 2,725 | $ | 49 | $ | 108,923 | $ | 2,993 | |||||||||||||||
其他減值（回收）和其他損失（收益），淨額(4) | 441 | (602) | 11,741 | 557 | |||||||||||||||||||
| 重組和與裁員相關的費用 | — | — | — | 1,368 | |||||||||||||||||||
災害相關費用（收入），淨額(5) | 1,792 | (367) | 588 | (610) | |||||||||||||||||||
| 調整總計 | $ | 4,958 | $ | (920) | $ | 121,252 | $ | 4,308 | |||||||||||||||
| 適用於普通股的調整後 FFO | $ | 316,205 | $ | 249,306 | $ | 907,128 | $ | 728,045 | |||||||||||||||
| 轉股單位和其他可稀釋單位的分發 | 4,571 | 2,341 | 11,537 | 7,022 | |||||||||||||||||||
| 調整後的攤薄基金運營所適用的普通股 | $ | 320,776 | $ | 251,647 | $ | 918,665 | $ | 735,067 | |||||||||||||||
| 攤薄後的調整基金運營所適用的加權平均股份 | 714,715 | 554,614 | 681,128 | 554,535 | |||||||||||||||||||
| 調整後的基金運營所適用的普通股 | $ | 316,205 | $ | 249,306 | $ | 907,128 | $ | 728,045 | |||||||||||||||
| 股票補償攤銷費用 | 3,755 | 3,434 | 11,935 | 10,966 | |||||||||||||||||||
| 延期融資成本和債務折扣（溢價）攤銷 | 7,408 | 3,054 | 19,247 | 8,828 | |||||||||||||||||||
直線租金(6) | (10,346) | (7,279) | (32,891) | (12,710) | |||||||||||||||||||
| AFFO資本支出 | (23,510) | (24,031) | (76,744) | (66,264) | |||||||||||||||||||
| 延遲所得稅 | 585 | (430) | 2,330 | (933) | |||||||||||||||||||
| 以上（以下）市場租賃無形資產的攤銷，淨額 | (7,887) | (5,626) | (23,325) | (20,267) | |||||||||||||||||||
| 其他經調整自由現金流（AFFO）項目 | (1,277) | (1,123) | (4,947) | (1,852) | |||||||||||||||||||
| 適用於普通股的AFFO | 284,933 | 217,305 | 802,733 | 645,813 | |||||||||||||||||||
| 可轉換股份和其他稀釋券的分配 | 4,576 | 2,340 | 11,671 | 7,026 | |||||||||||||||||||
| 用於普通股的攤薄AFFO | $ | 289,509 | $ | 219,645 | $ | 814,404 | $ | 652,839 | |||||||||||||||
| 加權平均股份數-攤薄AFFO | 714,715 | 554,614 | 681,128 | 554,535 | |||||||||||||||||||
| 7 | ||||
| 協調 | ||
| 所有基金類型資金運營資產 | ||||||||||||||
以千爲單位，每股數據除外
| 三個月之內結束 2020年9月30日 | 九個月結束 2020年9月30日 | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| 稀釋每股收益 | $ | 0.12 | $ | 0.12 | $ | 0.36 | $ | 0.43 | |||||||||||||||
| 折舊和攤銷 | 0.41 | 0.34 | 1.18 | 1.03 | |||||||||||||||||||
| 固定資產房地產業售賣盈虧，淨額 | (0.09) | — | (0.28) | (0.14) | |||||||||||||||||||
控制權變動盈虧，淨額(1) | 0.00 | — | (0.11) | 0.00 | |||||||||||||||||||
與房地產處置相關的稅收(2) | 0.00 | — | 0.02 | — | |||||||||||||||||||
| 每普通股攤薄後的Nareit FFO | $ | 0.44 | $ | 0.46 | $ | 1.17 | $ | 1.32 | |||||||||||||||
交易和併購相關項目(3) | 0.01 | 0.00 | 0.16 | 0.01 | |||||||||||||||||||
其他減值損失（收益）和其他損失（收益），淨額(4) | 0.00 | (0.01) | 0.02 | 0.00 | |||||||||||||||||||
| 重組和與裁員有關的費用 | — | — | — | 0.00 | |||||||||||||||||||
災害相關費用（收入），淨額(5) | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
| 每普通股調整後的攤薄FFO | $ | 0.45 | $ | 0.45 | $ | 1.35 | $ | 1.33 | |||||||||||||||
| 股權報酬攤銷支出 | 0.01 | 0.01 | 0.02 | 0.03 | |||||||||||||||||||
| 推遲融資成本和債務折扣（溢價）的攤銷 | 0.01 | 0.01 | 0.03 | 0.02 | |||||||||||||||||||
直線租金(6) | (0.02) | (0.01) | (0.05) | (0.02) | |||||||||||||||||||
| 調整後基金可分配現金淨收益資本支出 | (0.03) | (0.05) | (0.11) | (0.14) | |||||||||||||||||||
| 延遲所得稅 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
| 市場租賃（借準）無形資產攤銷淨額 | (0.01) | (0.01) | (0.03) | (0.04) | |||||||||||||||||||
| 其他調整後基金可分配現金淨收益 | 0.00 | 0.00 | (0.01) | 0.00 | |||||||||||||||||||
| 每股稀釋後基金可分配現金淨收益 | $ | 0.41 | $ | 0.40 | $ | 1.20 | $ | 1.18 | |||||||||||||||
______________________________________
(1)2024年9月30日結束的九個月中，涉及在加利福尼亞聖迭戈出售兩棟實驗室大樓的65%權益變動所產生的收益。此變動所產生的收益已記入綜合經營利潤表中的其他收入（費用），淨額。
(2)2024年9月30日結束的九個月包括與在加利福尼亞聖迭戈出售兩棟實驗樓的65%股權相關的非現金所得稅支出。
(3)2024年9月30日結束的三個月和九個月包括與合併相關的成本，主要由諮詢、法律、會計、稅務、合併後割離和股票補償支出以及在該期間與physicians realty trust進行業務合併的其他成本組成。這些成本部分被400萬美元的終止費用收入抵消，分別爲2024年9月30日結束的三個月和九個月，與Graphite Bio, Inc.相關，該公司於2024年3月後與LENZ Therapeutics, Inc.合併，此後將租賃條款修改以加速到2024年12月到期。其餘的400萬美元終止費用收入將在2024年第四季度確認。終止費用收入包括在綜合經營報告的租賃和相關收入中，但被排除在Healthpeak對投資組合現金房地產收入和調整後FFO的定義之外。
(4)2024年9月30日和2023年第三季度包括在運營綜合帳戶中的預期貸款損失儲備和（收益），以及貸款損失儲備（收益）和淨損失。
(5)與傷亡相關的費用（收回），均在綜合利潤（損失），及在綜合利益（損失）帳戶的未合併機動合營企業中確認。
(6)2023年9月30日結束的九個月包括一筆900萬美元在Sorrento Therapeutics, Inc.推行根據美國破產法第11章自願重組程序直線租金應收賬款的減值。該項活動反映在合併利潤表中，作爲租賃和相關收入的減少。
| 8 | ||||
| 協調 | ||
2024年度指導原則(1) | ||||||||||||||
每股數據
| 2024年指導範圍 | |||||||||||
| 收盤最低價 | 高中 | ||||||||||
| 稀釋每股收益 | $ | 0.40 | $ | 0.42 | |||||||
| 房地產業相關的折舊和攤銷 | 1.55 | 1.55 | |||||||||
| Healthpeak在未合併聯營企業中與房地產相關的折舊和攤銷份額 | 0.07 | 0.07 | |||||||||
| 非控股權益在房地產相關的折舊和攤銷中的份額 | (0.03) | (0.03) | |||||||||
| 房地產業折舊房地產的出售損益淨額 | (0.28) | (0.28) | |||||||||
| 控制權變更的損益淨額 | (0.12) | (0.12) | |||||||||
| 與房地產處置相關的稅款 | 0.02 | 0.02 | |||||||||
| 每普通股攤薄後的Nareit FFO | $ | 1.61 | $ | 1.63 | |||||||
| 交易和併購相關項目 | $ | 0.16 | $ | 0.16 | |||||||
| 其他減值（回收）和其他損失（收益），淨額 | 0.02 | 0.02 | |||||||||
| 每普通股調整後的攤薄FFO | $ | 1.79 | $ | 1.81 | |||||||
| 股票補償攤銷費用 | $ | 0.03 | $ | 0.03 | |||||||
| 延期融資成本和債務折扣（溢價）攤銷 | 0.05 | 0.05 | |||||||||
| 直線租金 | (0.07) | (0.07) | |||||||||
| AFFO資本支出 | (0.18) | (0.18) | |||||||||
| 以上（以下）市場租賃無形資產的攤銷，淨額 | (0.05) | (0.05) | |||||||||
| 其他經調整自由現金流（AFFO）項目 | (0.01) | (0.01) | |||||||||
| 每股稀釋後基金可分配現金淨收益 | $ | 1.56 | $ | 1.58 | |||||||
______________________________________
(1)上述預測反映了管理層截至2024年10月24日對當前和未來市場狀況的看法，包括關於租金率、入住率、開發項目以及我們於2024年10月24日發佈的營收新聞稿中提到的事件對盈利的影響的假設。然而，這些預測不包括未宣佈的未來交易的影響，除本文所述外。我們的實際結果可能與上述預測有實質性差異。除非法律另有規定，管理層不承擔更新上述預測的任何義務，並在此聲明不承擔因新信息、新發展或未來事件而更新上述預測的任何義務。
| 9 | ||||
| 協調 | ||
2024年度指導原則(1) | ||||||||||||||
單位爲百萬
預計2024年（低）
| 總投資組合 | |||||
| 淨利潤 | $ | 295 | |||
| 房地產業相關的折舊和攤銷 | 1,050 | ||||
| 房地產業折舊房地產的出售損益淨額 | (188) | ||||
| 其他減值（回收）和其他損失（收益），淨額 | 11 | ||||
| 其他收入、成本和費用調整爲現金（調整後）淨營收 | 314 | ||||
| 現金（調整後）淨營收 | $ | 1,482 | |||
| 合併前的遺留醫師房地產信託調整後的淨營收 | 53 | ||||
| 合併後的非同店調整後淨營業收入 | (183) | ||||
合併後的總同店現金（調整後）淨營業收入(2) | $ | 1,352 | |||
預計2024年（高）
| 總投資組合 | |||||
| 淨利潤 | $ | 309 | |||
| 房地產業相關的折舊和攤銷 | 1,050 | ||||
| 房地產業折舊房地產的出售損益淨額 | (188) | ||||
| 其他減值（回收）和其他損失（收益），淨額 | 11 | ||||
| 現金（調整後）淨營業收入的其他收入、成本和費用調整 | 314 | ||||
| 現金（調整後）淨營業收入 | $ | 1,496 | |||
| 合併前的傳統physicians realty trust調整後的淨營業收入 | 53 | ||||
| 合併後的非同店調整淨營業收入 | (184) | ||||
合併後的總同店現金（調整後）淨營業收入(2) | $ | 1,365 | |||
截至2023年12月31日的年度報告
| 總投資組合 | |||||
| 淨利潤 | $ | 335 | |||
| 房地產業相關的折舊和攤銷 | 750 | ||||
| 房地產業折舊房地產的出售損益淨額 | (86) | ||||
| 其他減值（回收）和其他損失（收益），淨額 | (6) | ||||
| 其他收入、成本和費用調整爲現金（調整後）淨營收 | 212 | ||||
| 現金（調整後）淨營收 | $ | 1,205 | |||
| 合併前的遺留醫師房地產信託調整後的淨營收 | 312 | ||||
| 合併後的非同店調整後淨營業收入 | (212) | ||||
合併後的總同店現金（調整後）淨營業收入(2) | $ | 1,306 | |||
持續
| 10 | ||||
| 協調 | ||
2024年度指導原則(1) | ||||||||||||||
單位爲百萬
2024財年全年預期併購-合併現金同店銷售額
| 收盤最低價 | 3.50 | % | |||
| 高 | 4.50 | % | |||
______________________________________
(1)前述的預測反映了管理層截至2024年10月24日對當前和未來市場狀況的看法，其中包括對租金率、入住率、開發項目以及我們在2024年10月24日發佈的盈利新聞稿中提到的事件對收益的影響的假設。然而，這些預測不反映未宣佈的未來交易的影響，除非在此處描述。我們的實際結果可能與上述預測有實質差異。除非法律另有規定，管理層不承擔任何義務，並在此聲明不會更新前述任何預測，因爲有新信息或新的或未來的進展。由於四捨五入而可能無法覈對或重新計算。
(2)總併購-合併同店現金淨營業收入（調整後）包括符合同店定義的傳統醫師地產信託物業的經營結果，就像它們在所呈現的整個時段內由公司擁有一樣。
| 11 | ||||
| 協調 | ||
| 企業總資產 | ||||||||||||||
以千爲單位
| 2024年9月30日 | |||||
合併總資產(1) | $ | 19,969,766 | |||
| 對非合併合資企業的投資和預付款 | (931,844) | ||||
| 房地產累計折舊和攤銷 | 3,925,375 | ||||
| 房地產無形資產累計攤銷 | 597,460 | ||||
| 合併總資產 | $ | 23,560,757 | |||
| Healthpeak在未納入合併範圍的合資企業總資產中所佔份額 | 1,373,382 | ||||
| 企業總資產 | $ | 24,934,139 | |||
______________________________________
(1)合併總資產是指2024年9月30日財務報表中的總資產，在2024年9月30日季度收益發布和補充報告的第8頁呈現。
| 投資組合投資 | ||
以千爲單位
| 2024年9月30日 | |||||||||||||||||||||||||||||
| 門診 醫療 | 實驗室 | CCRC | 其他 | 總費用 | |||||||||||||||||||||||||
| 淨房地產 | $ | 7,085,319 | $ | 7,150,002 | $ | 1,657,091 | $ | — | $ | 15,892,412 | |||||||||||||||||||
| 無形資產, 淨額 | 749,960 | 60,193 | 88,226 | — | 898,379 | ||||||||||||||||||||||||
| 房地產累計折舊和攤銷 | 1,929,183 | 1,577,724 | 418,468 | — | 3,925,375 | ||||||||||||||||||||||||
| 房地產無形資產累計攤銷 | 278,110 | 70,898 | 248,452 | — | 597,460 | ||||||||||||||||||||||||
| Healthpeak對未納入合併範圍的聯營企業毛房地產資產的份額 | 235,870 | 568,902 | — | 474,184 | 1,278,956 | ||||||||||||||||||||||||
| 完全折舊和攤銷的房地產和無形資產 | 752,477 | 572,089 | 25,369 | — | 1,349,935 | ||||||||||||||||||||||||
| 租賃佣金和其他 | 177,616 | 97,482 | — | — | 275,098 | ||||||||||||||||||||||||
| 債務投資 | — | — | — | 631,164 | 631,164 | ||||||||||||||||||||||||
| 房地產無形負債，總額 | (241,895) | (190,922) | — | — | (432,817) | ||||||||||||||||||||||||
| 非控股利益在合併聯營創業公司房地產及相關無形資產中的份額 | (418,228) | — | — | — | (418,228) | ||||||||||||||||||||||||
| 投資組合 | $ | 10,548,412 | $ | 9,906,368 | $ | 2,437,606 | $ | 1,105,348 | $ | 23,997,734 | |||||||||||||||||||
| 12 | ||||
| 協調 | ||
| 收入 | ||
以千爲單位
| 三個月之內結束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 門診醫療 | $ | 191,016 | $ | 188,835 | $ | 238,272 | $ | 332,515 | $ | 317,659 | ||||||||||||||||||||||
| 實驗室 | 226,059 | 223,497 | 223,761 | 214,266 | 225,592 | |||||||||||||||||||||||||||
| CCRC | 133,808 | 136,341 | 138,776 | 140,891 | 142,845 | |||||||||||||||||||||||||||
| 其他 | 5,360 | 4,979 | 5,059 | 6,878 | 13,126 | |||||||||||||||||||||||||||
| 企業非分割 | — | — | 692 | 954 | 1,175 | |||||||||||||||||||||||||||
| 總收入 | $ | 556,243 | $ | 553,652 | $ | 606,560 | $ | 695,504 | $ | 700,397 | ||||||||||||||||||||||
| 門診醫療 | — | — | — | — | — | |||||||||||||||||||||||||||
| 實驗室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | (5,360) | (4,979) | (5,059) | (6,878) | (13,126) | |||||||||||||||||||||||||||
| 公司非分部 | — | — | (692) | (954) | (1,175) | |||||||||||||||||||||||||||
| 減：利息收入和其他 | $ | (5,360) | $ | (4,979) | $ | (5,751) | $ | (7,832) | $ | (14,301) | ||||||||||||||||||||||
| 門診醫療 | 746 | 788 | 2,739 | 6,903 | 7,065 | |||||||||||||||||||||||||||
| 實驗室 | 2,425 | 3,406 | 4,861 | 4,301 | 5,242 | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | 20,572 | 21,247 | 21,533 | 21,378 | 21,886 | |||||||||||||||||||||||||||
| 公司非分部 | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak的非合併合資房地產業收入份額 | $ | 23,743 | $ | 25,441 | $ | 29,133 | $ | 32,582 | $ | 34,193 | ||||||||||||||||||||||
| 門診醫療 | — | — | — | — | — | |||||||||||||||||||||||||||
| 實驗室 | — | — | — | — | — | |||||||||||||||||||||||||||
| 退休社區連續護理中心（CCRC） | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | 1 | — | — | — | |||||||||||||||||||||||||||
| 企業非分部 | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak對未納入合併的聯營創業公司政府補助收入的份額 | $ | — | $ | 1 | $ | — | $ | — | $ | — | ||||||||||||||||||||||
| 門診醫療 | (8,735) | (8,710) | (8,876) | (9,341) | (9,734) | |||||||||||||||||||||||||||
| 實驗室 | (154) | (171) | (163) | (33) | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 非控股利益份額佔合併合資房地產業收入 | $ | (8,889) | $ | (8,881) | $ | (9,039) | $ | (9,374) | $ | (9,734) | ||||||||||||||||||||||
持續
| 13 | ||||
| 協調 | ||
| 收入 | ||
以千爲單位
| 三個月之內結束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 門診醫療 | $ | (4,223) | $ | (3,612) | $ | (7,011) | $ | (12,101) | $ | (12,761) | ||||||||||||||||||||||
| 實驗室 | (9,477) | (10,296) | (21,127) | (12,988) | (16,647) | |||||||||||||||||||||||||||
| CCRC | — | (1) | 1 | (1) | — | |||||||||||||||||||||||||||
| 其他 | (5) | (81) | (56) | (18) | (71) | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 房地產業收入的非現金調整 | $ | (13,705) | $ | (13,990) | $ | (28,193) | $ | (25,108) | $ | (29,479) | ||||||||||||||||||||||
| 門診醫療 | 178,804 | 177,301 | 225,124 | 317,976 | 302,229 | |||||||||||||||||||||||||||
| 實驗室 | 218,854 | 216,436 | 207,332 | 205,546 | 214,187 | |||||||||||||||||||||||||||
| CCRC | 133,808 | 136,340 | 138,777 | 140,890 | 142,845 | |||||||||||||||||||||||||||
| 其他 | 20,567 | 21,167 | 21,477 | 21,360 | 21,815 | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
投資組合現金房地產營業收入(1) | $ | 552,033 | $ | 551,244 | $ | 592,710 | $ | 685,772 | $ | 681,076 | ||||||||||||||||||||||
| 門診醫療 | 118,985 | 79,143 | 90,529 | — | — | |||||||||||||||||||||||||||
| 實驗室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合併前遺留的physicians realty trust現金房地產營業收入 | $ | 118,985 | $ | 79,143 | $ | 90,529 | $ | — | $ | — | ||||||||||||||||||||||
| 門診醫療 | (11,656) | 24,537 | (30,583) | (30,287) | (11,119) | |||||||||||||||||||||||||||
| 實驗室 | (44,985) | (44,147) | (33,468) | (28,911) | (32,564) | |||||||||||||||||||||||||||
| CCRC | (205) | (257) | (299) | (306) | (304) | |||||||||||||||||||||||||||
| 其他 | (20,567) | (21,167) | (21,477) | (21,360) | (21,815) | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合併後的非自持房地產營業收入 | $ | (77,413) | $ | (41,034) | $ | (85,827) | $ | (80,864) | $ | (65,802) | ||||||||||||||||||||||
| 門診醫療 | 286,133 | 280,981 | 285,070 | 287,689 | 291,110 | |||||||||||||||||||||||||||
| 實驗室 | 173,869 | 172,289 | 173,864 | 176,635 | 181,623 | |||||||||||||||||||||||||||
| CCRC | 133,603 | 136,083 | 138,478 | 140,584 | 142,541 | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
合併後的社保現金房地產業營業收入(3) | $ | 593,605 | $ | 589,353 | $ | 597,412 | $ | 604,908 | $ | 615,274 | ||||||||||||||||||||||
| 14 | ||||
| 協調 | ||
| 研究和開發 | ||
以千爲單位
| 三個月之內結束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 門診醫療 | $ | 67,693 | $ | 65,691 | $ | 81,268 | $ | 111,702 | $ | 106,484 | ||||||||||||||||||||||
| 實驗室 | 60,268 | 56,964 | 56,840 | 56,656 | 64,075 | |||||||||||||||||||||||||||
| CCRC | 104,773 | 105,920 | 105,621 | 105,469 | 109,720 | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
| 營業費用 | $ | 232,734 | $ | 224,401 | $ | 243,729 | $ | 273,827 | $ | 280,279 | ||||||||||||||||||||||
| 門診醫療 | 301 | 295 | 1,083 | 2,464 | 2,832 | |||||||||||||||||||||||||||
| 實驗室 | 958 | 1,104 | 1,324 | 1,528 | 1,811 | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | 15,439 | 15,748 | 16,099 | 15,790 | 16,226 | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| Healthpeak的非合併聯營企業營業費用分配 | $ | 16,698 | $ | 17,147 | $ | 18,506 | $ | 19,782 | $ | 20,869 | ||||||||||||||||||||||
| 門診醫療 | (2,474) | (2,443) | (2,430) | (2,609) | (2,851) | |||||||||||||||||||||||||||
| 實驗室 | (33) | (48) | (43) | (9) | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 非控股權益的合併聯營企業營業費用分配 | $ | (2,507) | $ | (2,491) | $ | (2,473) | $ | (2,618) | $ | (2,851) | ||||||||||||||||||||||
| 門診醫療 | — | — | — | — | — | |||||||||||||||||||||||||||
| 實驗室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
| 非資產級別的營業費用 | $ | — | $ | (4,174) | $ | — | $ | — | $ | — | ||||||||||||||||||||||
| 門診醫療 | (676) | (675) | (884) | (1,671) | (1,741) | |||||||||||||||||||||||||||
| 實驗室 | 365 | 612 | 308 | 301 | 253 | |||||||||||||||||||||||||||
| CCRC | — | 940 | 1 | 1,738 | (95) | |||||||||||||||||||||||||||
| 其他 | 22 | (505) | (9) | (244) | 3 | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 對營業費用的非現金調整 | $ | (289) | $ | 372 | $ | (584) | $ | 124 | $ | (1,580) | ||||||||||||||||||||||
| 門診醫療 | 64,844 | 62,868 | 79,037 | 109,886 | 104,724 | |||||||||||||||||||||||||||
| 實驗室 | 61,558 | 58,632 | 58,429 | 58,476 | 66,139 | |||||||||||||||||||||||||||
| CCRC | 104,773 | 106,860 | 105,622 | 107,207 | 109,625 | |||||||||||||||||||||||||||
| 其他 | 15,461 | 15,243 | 16,090 | 15,546 | 16,229 | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
投資組合現金營業費用(2) | $ | 246,636 | $ | 243,603 | $ | 259,178 | $ | 291,115 | $ | 296,717 | ||||||||||||||||||||||
持續
| 15 | ||||
| 協調 | ||
| 研究和開發 | ||
以千爲單位
| 三個月之內結束 | ||||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| 門診醫療 | $ | 40,172 | $ | 36,580 | $ | 29,131 | $ | — | $ | — | ||||||||||||||||||||||
| 實驗室 | — | — | — | — | — | |||||||||||||||||||||||||||
| CCRC | — | — | — | — | — | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合併前的傳統醫療房地產信託現金營業費用 | $ | 40,172 | $ | 36,580 | $ | 29,131 | $ | — | $ | — | ||||||||||||||||||||||
| 門診醫療 | (5,287) | (5,343) | (11,088) | (11,999) | (6,353) | |||||||||||||||||||||||||||
| 實驗室 | (8,679) | (8,862) | (7,767) | (7,555) | (8,913) | |||||||||||||||||||||||||||
| CCRC | (537) | (504) | (627) | (440) | (635) | |||||||||||||||||||||||||||
| 其他 | (15,461) | (15,243) | (16,090) | (15,546) | (16,229) | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
| 合併後的非SS現金營業費用 | $ | (29,964) | $ | (29,952) | $ | (35,572) | $ | (35,540) | $ | (32,130) | ||||||||||||||||||||||
| 門診醫療 | 99,729 | 94,105 | 97,080 | 97,887 | 98,371 | |||||||||||||||||||||||||||
| 實驗室 | 52,879 | 49,770 | 50,662 | 50,921 | 57,226 | |||||||||||||||||||||||||||
| CCRC | 104,236 | 106,356 | 104,995 | 106,767 | 108,990 | |||||||||||||||||||||||||||
| 其他 | — | — | — | — | — | |||||||||||||||||||||||||||
| 企業非區段 | — | — | — | — | — | |||||||||||||||||||||||||||
合併後的SS現金營業費用(3) | $ | 256,844 | $ | 250,231 | $ | 252,737 | $ | 255,575 | $ | 264,587 | ||||||||||||||||||||||
| 16 | ||||
| 協調 | ||
| 營業收入 | 研究和開發 | |||||||
以千爲單位
| 九個月結束 2024年9月30日 | 九個月結束 2024年9月30日 | ||||||||||||||||
| 門診醫療 | $ | 888,446 | 門診醫療 | $ | 299,455 | ||||||||||||
| 實驗室 | 663,619 | 實驗室 | 177,571 | ||||||||||||||
| CCRC | 422,512 | CCRC | 320,809 | ||||||||||||||
| 其他 | 25,063 | 其他 | — | ||||||||||||||
| 企業非區段 | 2,821 | 企業非區段 | — | ||||||||||||||
| 總收入 | $ | 2,002,461 | 營業費用 | $ | 797,835 | ||||||||||||
| 門診醫療 | — | 門診醫療 | 6,380 | ||||||||||||||
| 實驗室 | — | 實驗室 | 4,663 | ||||||||||||||
| CCRC | — | CCRC | — | ||||||||||||||
| 其他 | (25,063) | 其他 | 48,116 | ||||||||||||||
| 企業非區段 | (2,821) | 企業非區段 | — | ||||||||||||||
| 減：利息收入和其他 | $ | (27,884) | Healthpeak的非合併聯營企業營業費用分配 | $ | 59,159 | ||||||||||||
| 門診醫療 | 16,707 | 門診醫療 | (7,889) | ||||||||||||||
| 實驗室 | 14,404 | 實驗室 | (52) | ||||||||||||||
| CCRC | — | CCRC | — | ||||||||||||||
| 其他 | 64,797 | 其他 | — | ||||||||||||||
| 企業非區段 | — | 企業非區段 | — | ||||||||||||||
| Healthpeak的非合併合資房地產業收入份額 | $ | 95,908 | 非控股權益的合併聯營企業營業費用分配 | $ | (7,941) | ||||||||||||
| 門診醫療 | (27,952) | 門診醫療 | (4,299) | ||||||||||||||
| 實驗室 | (196) | 實驗室 | 862 | ||||||||||||||
| CCRC | — | CCRC | 1,645 | ||||||||||||||
| 其他 | — | 其他 | (251) | ||||||||||||||
| 企業非區段 | — | 企業非區段 | — | ||||||||||||||
| 非控股利益份額佔合併合資房地產業收入 | $ | (28,148) | 對營業費用的非現金調整 | $ | (2,043) | ||||||||||||
| 門診醫療 | (31,872) | 門診醫療 | 293,647 | ||||||||||||||
| 實驗室 | (50,762) | 實驗室 | 183,044 | ||||||||||||||
| CCRC | — | CCRC | 322,454 | ||||||||||||||
| 其他 | (145) | 其他 | 47,865 | ||||||||||||||
| 企業非區段 | — | 企業非區段 | — | ||||||||||||||
| 房地產業收入的非現金調整 | $ | (82,779) | 投資組合現金營業費用(2) | $ | 847,010 | ||||||||||||
| 門診醫療 | 845,329 | 門診醫療 | 29,131 | ||||||||||||||
| 實驗室 | 627,065 | 生命科學 | — | ||||||||||||||
| CCRC | 422,512 | CCRC | — | ||||||||||||||
| 其他 | 64,652 | 其他 | — | ||||||||||||||
| 企業非區段 | — | 企業非部門 | — | ||||||||||||||
投資組合現金房地產營業收入(1) | $ | 1,959,558 | 合併前的傳統醫療房地產信託現金營業費用 | $ | 29,131 | ||||||||||||
持續
| 17 | ||||
| 協調 | ||
| 營業收入 | 研究和開發 | |||||||
以千爲單位
| 九個月已結束 2024年9月30日 | 九個月已結束 2024年9月30日 | ||||||||||||||||
| 門診醫療 | $ | 90,529 | 門診醫療 | $ | (31,378) | ||||||||||||
| 實驗室 | — | 實驗室 | (31,204) | ||||||||||||||
| CCRC | — | CCRC | (1,702) | ||||||||||||||
| 其他 | — | 其他 | (47,865) | ||||||||||||||
| 企業非細分市場 | — | 企業非細分市場 | — | ||||||||||||||
| 合併前的遺產 Physicians Realty Trust 現金房地產收入 | $ | 90,529 | 合併合併後的非 SS 現金運營費用 | $ | (112,149) | ||||||||||||
| 門診醫療 | (76,485) | 門診醫療 | 291,400 | ||||||||||||||
| 實驗室 | (113,111) | 實驗室 | 151,840 | ||||||||||||||
| CCRC | (909) | CCRC | 320,752 | ||||||||||||||
| 其他 | (64,652) | 其他 | — | ||||||||||||||
| 企業非細分市場 | — | 企業非細分市場 | — | ||||||||||||||
| 合併後的非 SS 現金房地產收入 | $ | (255,157) | 合併合併後的 SS 現金運營費用(3) | $ | 763,992 | ||||||||||||
| 門診醫療 | 859,373 | ||||||||||||||||
| 實驗室 | 513,954 | ||||||||||||||||
| CCRC | 421,603 | ||||||||||||||||
| 其他 | — | ||||||||||||||||
| 企業非細分市場 | — | ||||||||||||||||
合併後的SS現金房地產收入(3) | $ | 1,794,930 | |||||||||||||||
______________________________________
(1)投資組合現金房地產收入消除了直線租金、市場租賃無形資產攤銷、租賃終止費以及遞延社區費收入的影響。
(2)投資組合現金營業費用消除了直線租金、租約終止費用、已發生但尚未報告的保險索賠的精算準備以及延期社區費用支出的影響。
(3)合併後的同店現金房地產收入和合並後的同店現金營業費用包括符合同店定義的傳統Physicians Realty Trust房產的運營結果，就好像它們在所展示的全部期間內被公司擁有一樣。
| 18 | ||||
| 協調 | ||
| 分段組合淨運營收入和現金（調整後）淨運營收入、組合收入和SS | ||
以千爲單位
| 總投資組合 | 三個月之內結束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 68,656 | $ | 75,395 | $ | 11,177 | $ | 152,716 | $ | 92,738 | |||||||||||||||||||||||
| 利息收入和其他 | (5,360) | (4,979) | (5,751) | (7,832) | (14,301) | |||||||||||||||||||||||||||
| 利息支出 | 50,510 | 52,784 | 60,907 | 74,910 | 74,105 | |||||||||||||||||||||||||||
| 折舊和攤銷 | 184,559 | 188,544 | 219,219 | 283,498 | 280,019 | |||||||||||||||||||||||||||
| ZSCALER, INC. | 23,093 | 21,556 | 23,299 | 26,718 | 23,216 | |||||||||||||||||||||||||||
| 交易和合並相關成本 | 36 | 14,417 | 107,220 | 7,759 | 7,134 | |||||||||||||||||||||||||||
| 淨減值損失和貸款損失準備 | (550) | (5,445) | 11,458 | (553) | 441 | |||||||||||||||||||||||||||
| 房地產業銷售淨收益（損失） | — | — | (3,255) | (122,044) | (62,325) | |||||||||||||||||||||||||||
| 其他（收入）支出，淨額 | (1,481) | (2,600) | (78,516) | (4,004) | (982) | |||||||||||||||||||||||||||
| 所得稅（收益）費用 | 787 | (11,842) | 13,698 | 2,728 | 1,938 | |||||||||||||||||||||||||||
| 合營創業公司的股權（收入）損失 | (2,101) | (3,558) | (2,376) | (51) | 3,834 | |||||||||||||||||||||||||||
| Healthpeak在非合併創業公司淨營業收入中的份額 | 7,045 | 8,295 | 10,627 | 12,800 | 13,324 | |||||||||||||||||||||||||||
| 非控制權益在合併創業公司淨營業收入中的份額 | (6,382) | (6,390) | (6,566) | (6,756) | (6,883) | |||||||||||||||||||||||||||
| 非物業級淨營業收入 | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
淨營業收入調整(1) | (13,416) | (14,361) | (27,609) | (25,232) | (27,899) | |||||||||||||||||||||||||||
| 投資組合調整後的淨營業收入 | $ | 305,396 | $ | 307,642 | $ | 333,532 | $ | 394,657 | $ | 384,359 | ||||||||||||||||||||||
| 合併前的傳統physicians realty trust調整後的淨營業收入 | 78,814 | 42,563 | 61,398 | — | — | |||||||||||||||||||||||||||
| 合併後的非同店調整淨營業收入 | (47,449) | (11,083) | (50,255) | (45,324) | (33,672) | |||||||||||||||||||||||||||
合併後的自有物業淨營業收入調整後(2) | $ | 336,761 | $ | 339,122 | $ | 344,675 | $ | 349,333 | $ | 350,687 | ||||||||||||||||||||||
門診醫療 | 三個月之內結束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 48,906 | $ | 48,580 | $ | 49,684 | $ | 108,586 | $ | 94,960 | |||||||||||||||||||||||
| 利息支出 | 1,947 | 1,979 | 3,131 | 4,070 | 4,268 | |||||||||||||||||||||||||||
| 折舊和攤銷 | 72,736 | 74,067 | 106,292 | 173,408 | 168,120 | |||||||||||||||||||||||||||
| 交易和合並相關成本 | 23 | 949 | 113 | 41 | 889 | |||||||||||||||||||||||||||
| 房地產業銷售的（收益）損失，淨額 | — | — | (3,255) | (66,831) | (62,325) | |||||||||||||||||||||||||||
| 其他（收入）支出，淨額 | (78) | (2,180) | (71) | (1,383) | 78 | |||||||||||||||||||||||||||
| 與未納入合併財務報表的合營企業相關的股權（收益）損失 | (211) | (251) | 1,110 | 2,922 | 5,185 | |||||||||||||||||||||||||||
| Healthpeak在未納入合併財務報表的合營企業淨營業收入中的份額 | 445 | 493 | 1,656 | 4,439 | 4,233 | |||||||||||||||||||||||||||
| 非控股權益在合併財務報表中的合營企業淨營業收入中的份額 | (6,261) | (6,267) | (6,446) | (6,732) | (6,883) | |||||||||||||||||||||||||||
淨營業收入的調整(1) | (3,547) | (2,938) | (6,127) | (10,430) | (11,020) | |||||||||||||||||||||||||||
| 投資組合調整後的淨營業收入 | $ | 113,960 | $ | 114,432 | $ | 146,087 | $ | 208,090 | $ | 197,505 | ||||||||||||||||||||||
| 合併前的傳統physicians realty trust調整後的淨營業收入 | 78,814 | 42,563 | 61,398 | — | — | |||||||||||||||||||||||||||
| 合併後的非同店調整淨營業收入 | (6,370) | 29,881 | (19,495) | (18,288) | (4,766) | |||||||||||||||||||||||||||
合併後的SS調整後的淨營業收入(2) | $ | 186,404 | $ | 186,876 | $ | 187,990 | $ | 189,802 | $ | 192,739 | ||||||||||||||||||||||
持續
| 19 | ||||
| 協調 | ||
| 分段投資組合淨營業收入和現金（調整後）淨營業收入，投資組合收入和SS | ||
以千爲單位
| 實驗室 | 三個月之內結束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 88,337 | $ | 86,913 | $ | 169,798 | $ | 138,830 | $ | 85,240 | |||||||||||||||||||||||
| 折舊和攤銷 | 78,646 | 80,886 | 78,908 | 75,947 | 77,625 | |||||||||||||||||||||||||||
| 交易和合並相關成本 | 51 | 124 | 9 | 478 | 4 | |||||||||||||||||||||||||||
| 房地產業銷售的淨(收益)損失 | — | — | — | (55,213) | — | |||||||||||||||||||||||||||
| 其他（收入）支出，淨額 | 1 | (6) | (78,983) | (185) | 402 | |||||||||||||||||||||||||||
| 股權(收入)分擔未納入合併範圍的合資公司損失 | (1,244) | (1,384) | (2,811) | (2,247) | (1,754) | |||||||||||||||||||||||||||
| Healthpeak在未納入合併範圍的合資企業的分擔淨運營收入 | 1,467 | 2,302 | 3,537 | 2,773 | 3,431 | |||||||||||||||||||||||||||
| 非控制利益在合併範圍內的合資企業淨運營收入中的份額 | (121) | (123) | (120) | (24) | — | |||||||||||||||||||||||||||
對淨運營收入的調整(1) | (9,842) | (10,907) | (21,435) | (13,289) | (16,900) | |||||||||||||||||||||||||||
| 投資組合調整後淨營業收入 | $ | 157,295 | $ | 157,805 | $ | 148,903 | $ | 147,070 | $ | 148,048 | ||||||||||||||||||||||
| 合併後的非同店調整淨營業收入 | (36,305) | (35,286) | (25,701) | (21,356) | (23,651) | |||||||||||||||||||||||||||
合併後淨營業收入(2) | $ | 120,990 | $ | 122,519 | $ | 123,202 | $ | 125,714 | $ | 124,397 | ||||||||||||||||||||||
| CCRC | 三個月之內結束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | (5,633) | $ | (6,213) | $ | (2,172) | $ | (160) | $ | (2,827) | |||||||||||||||||||||||
| 利息支出 | 1,830 | 1,541 | 996 | 984 | 984 | |||||||||||||||||||||||||||
| 折舊和攤銷 | 33,177 | 33,591 | 34,019 | 34,143 | 34,274 | |||||||||||||||||||||||||||
| 交易和合並相關成本 | (85) | 1,469 | 73 | (24) | — | |||||||||||||||||||||||||||
| 其他（收入）支出，淨額 | (254) | 33 | 239 | 479 | 694 | |||||||||||||||||||||||||||
調整淨利潤(1) | — | (940) | — | (1,739) | 95 | |||||||||||||||||||||||||||
| 投資組合調整後的淨利潤 | $ | 29,035 | $ | 29,481 | $ | 33,155 | $ | 33,683 | $ | 33,220 | ||||||||||||||||||||||
| 合併後的非同店調整淨營業收入 | 332 | 246 | 328 | 134 | 331 | |||||||||||||||||||||||||||
合併後的自存庫調整後淨利潤(2) | $ | 29,367 | $ | 29,727 | $ | 33,483 | $ | 33,817 | $ | 33,551 | ||||||||||||||||||||||
| 其他 | 三個月之內結束 | |||||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31號 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||||||
| $ | 6,503 | $ | 12,338 | $ | (5,724) | $ | 8,195 | $ | 12,282 | |||||||||||||||||||||||
| 利息收入和其他 | (5,360) | (4,979) | (5,059) | (6,878) | (13,126) | |||||||||||||||||||||||||||
| 減值損失和貸款準備金，淨 | (550) | (5,445) | 11,458 | (553) | 441 | |||||||||||||||||||||||||||
| 其他（收入）支出，淨額 | 53 | 9 | — | (38) | — | |||||||||||||||||||||||||||
| 其他（損失）聯營企業的股權收益 | (646) | (1,923) | (675) | (726) | 403 | |||||||||||||||||||||||||||
| Healthpeak在非合併聯營企業淨營業收入中所佔比例 | 5,133 | 5,500 | 5,434 | 5,588 | 5,660 | |||||||||||||||||||||||||||
調整後的淨營業收入(1) | (27) | 424 | (47) | 226 | (74) | |||||||||||||||||||||||||||
| 組合調整後的淨營業收入 | $ | 5,106 | $ | 5,924 | $ | 5,387 | $ | 5,814 | $ | 5,586 | ||||||||||||||||||||||
| 合併後的非同店調整淨營業收入 | (5,106) | (5,924) | (5,387) | (5,814) | (5,586) | |||||||||||||||||||||||||||
合併後的SS調整淨運營收入(2) | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||
持續
| 20 | ||||
| Reconciliations | ||
| Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS | ||
In thousands
Corporate Non-Segment | Three Months Ended | |||||||||||||||||||||||||||||||
| September 30, 2023 | December 31, 2023 | March 31, 2024 | June 30, 2024 | September 30, 2024 | ||||||||||||||||||||||||||||
| Net income (loss) | $ | (69,457) | $ | (66,223) | $ | (200,409) | $ | (102,735) | $ | (96,917) | ||||||||||||||||||||||
| Interest income and other | — | — | (692) | (954) | (1,175) | |||||||||||||||||||||||||||
| Interest expense | 46,733 | 49,264 | 56,780 | 69,856 | 68,853 | |||||||||||||||||||||||||||
| General and administrative | 23,093 | 21,556 | 23,299 | 26,718 | 23,216 | |||||||||||||||||||||||||||
| Transaction and merger-related costs | 47 | 11,875 | 107,025 | 7,264 | 6,241 | |||||||||||||||||||||||||||
| Other (income) expense, net | (1,203) | (456) | 299 | (2,877) | (2,156) | |||||||||||||||||||||||||||
| Income tax (benefit) expense | 787 | (11,842) | 13,698 | 2,728 | 1,938 | |||||||||||||||||||||||||||
| Non-property level NOI | — | (4,174) | — | — | — | |||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||||||
| 21 | ||||
| Reconciliations | ||
| Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS | ||
In thousands
For the nine months ended September 30, 2024
| Outpatient Medical | Lab | CCRC | Other Non- reportable | Corporate Non-segment | Total | |||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 253,425 | $ | 393,912 | $ | (5,159) | $ | 14,753 | $ | (400,300) | $ | 256,631 | ||||||||||||||||||||||||||
| Interest income and other | — | — | — | (25,063) | (2,821) | (27,884) | ||||||||||||||||||||||||||||||||
| Interest expense | 11,231 | — | 2,963 | — | 195,728 | 209,922 | ||||||||||||||||||||||||||||||||
| Depreciation and amortization | 447,819 | 232,480 | 102,437 | — | — | 782,736 | ||||||||||||||||||||||||||||||||
| General and administrative | — | — | — | — | 73,233 | 73,233 | ||||||||||||||||||||||||||||||||
| Transaction and merger-related costs | 1,043 | 490 | 49 | — | 120,531 | 122,113 | ||||||||||||||||||||||||||||||||
| Impairments and loan loss reserves, net | — | — | — | 11,346 | — | 11,346 | ||||||||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (132,369) | (55,255) | — | — | — | (187,624) | ||||||||||||||||||||||||||||||||
| Other (income) expense, net | (1,376) | (78,766) | 1,413 | (38) | (4,735) | (83,502) | ||||||||||||||||||||||||||||||||
| Income tax (benefit) expense | — | — | — | — | 18,364 | 18,364 | ||||||||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | 9,218 | (6,813) | — | (998) | — | 1,407 | ||||||||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 10,327 | 9,741 | — | 16,681 | — | 36,749 | ||||||||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (20,063) | (144) | — | — | — | (20,207) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) | (27,573) | (51,624) | (1,645) | 106 | — | (80,736) | ||||||||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 551,682 | $ | 444,021 | $ | 100,058 | $ | 16,787 | $ | — | $ | 1,112,548 | ||||||||||||||||||||||||||
| Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 61,398 | — | — | — | — | 61,398 | ||||||||||||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (45,107) | (81,907) | 793 | (16,787) | — | (143,008) | ||||||||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) | $ | 567,973 | $ | 362,114 | $ | 100,851 | $ | — | $ | — | $ | 1,030,938 | ||||||||||||||||||||||||||
| 22 | ||||
| Reconciliations | ||
| Segment Portfolio NOI and Cash (Adjusted) NOI, Portfolio Income, and SS | ||
In thousands
For the nine months ended September 30, 2023
| Outpatient Medical | Lab | CCRC | Other Non- reportable | Corporate Non-segment | Total | |||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 168,037 | $ | 298,145 | $ | (20,374) | $ | 24,445 | $ | (210,891) | $ | 259,362 | ||||||||||||||||||||||||||
| Interest income and other | — | — | — | (16,802) | — | (16,802) | ||||||||||||||||||||||||||||||||
| Interest expense | 5,791 | — | 5,470 | — | 136,286 | 147,547 | ||||||||||||||||||||||||||||||||
| Depreciation and amortization | 215,617 | 247,463 | 98,277 | — | — | 561,357 | ||||||||||||||||||||||||||||||||
| General and administrative | — | — | — | — | 73,576 | 73,576 | ||||||||||||||||||||||||||||||||
| Transaction and merger-related costs | 171 | 209 | 412 | — | 2,306 | 3,098 | ||||||||||||||||||||||||||||||||
| Impairments and loan loss reserves, net | — | — | — | (156) | — | (156) | ||||||||||||||||||||||||||||||||
| (Gain) loss on sales of real estate, net | (21,312) | (60,498) | — | (4,653) | — | (86,463) | ||||||||||||||||||||||||||||||||
| Other (income) expense, net | (517) | (1) | (260) | 72 | (3,502) | (4,208) | ||||||||||||||||||||||||||||||||
| Government grant income | — | — | 184 | — | — | 184 | ||||||||||||||||||||||||||||||||
| Income tax (benefit) expense | — | — | — | — | 2,225 | 2,225 | ||||||||||||||||||||||||||||||||
| Equity (income) loss from unconsolidated joint ventures | (585) | (3,155) | — | (2,906) | — | (6,646) | ||||||||||||||||||||||||||||||||
| Healthpeak's share of unconsolidated joint venture NOI | 1,350 | 3,532 | — | 16,346 | — | 21,228 | ||||||||||||||||||||||||||||||||
| Noncontrolling interests' share of consolidated joint venture NOI | (18,887) | (341) | — | — | — | (19,228) | ||||||||||||||||||||||||||||||||
Adjustments to NOI(1) | (11,373) | (25,618) | (679) | (59) | — | (37,729) | ||||||||||||||||||||||||||||||||
| Portfolio Adjusted NOI | $ | 338,292 | $ | 459,736 | $ | 83,030 | $ | 16,287 | $ | — | $ | 897,345 | ||||||||||||||||||||||||||
| Pre-Merger legacy Physicians Realty Trust Adjusted NOI | 233,483 | — | — | — | — | 233,483 | ||||||||||||||||||||||||||||||||
| Merger-Combined non-SS Adjusted NOI | (21,755) | (108,446) | 855 | (16,287) | — | (145,633) | ||||||||||||||||||||||||||||||||
Merger-Combined SS Adjusted NOI(2) | $ | 550,020 | $ | 351,290 | $ | 83,885 | $ | — | $ | — | $ | 985,195 | ||||||||||||||||||||||||||
(1)Adjustments to NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, lease termination fees, the impact of deferred community fee income, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fees expense.
(2)Merger-Combined Same-Store Adjusted NOI include the results from operations of the legacy Physicians Realty Trust properties that met the same-store definition as if they were owned by the Company for the entirety of the periods presented.
| 23 | ||||
| Reconciliations | ||
| Property Count Reconciliations | ||
| As of September 30, 2024 | |||||||||||||||||||||||||||||
| Property Count Reconciliation | |||||||||||||||||||||||||||||
| Outpatient Medical | Lab | CCRC | Other | Total | |||||||||||||||||||||||||
| Prior Quarter Total Property Count | 585 | 139 | 15 | 19 | 758 | ||||||||||||||||||||||||
| Assets sold | (59) | — | — | — | (59) | ||||||||||||||||||||||||
| New Developments | 1 | — | — | — | 1 | ||||||||||||||||||||||||
| Current Quarter Total Property Count | 527 | 139 | 15 | 19 | 700 | ||||||||||||||||||||||||
| Recent acquisitions | (3) | — | — | — | (3) | ||||||||||||||||||||||||
| Assets in Development | (7) | (4) | — | — | (11) | ||||||||||||||||||||||||
| Recently completed Developments | (1) | (1) | — | — | (2) | ||||||||||||||||||||||||
| Assets in Redevelopment | — | (17) | — | — | (17) | ||||||||||||||||||||||||
| Recently completed Redevelopments | (3) | (4) | — | — | (7) | ||||||||||||||||||||||||
| Segment exclusions | — | — | — | (19) | (19) | ||||||||||||||||||||||||
| Significant tenant relocation | — | (2) | — | — | (2) | ||||||||||||||||||||||||
| Three-Month SS Property Count | 513 | 111 | 15 | — | 639 | ||||||||||||||||||||||||
| Recent acquisitions | (2) | — | — | — | (2) | ||||||||||||||||||||||||
| Recently completed Redevelopments | (1) | (1) | — | — | (2) | ||||||||||||||||||||||||
| Nine-Month SS Property Count | 510 | 110 | 15 | — | 635 | ||||||||||||||||||||||||
| Sequential SS | |||||||||||||||||||||||||||||
| Outpatient Medical | Lab | CCRC | Other | Total | |||||||||||||||||||||||||
| Prior Quarter Three-Month SS Property Count | 569 | 112 | 15 | — | 696 | ||||||||||||||||||||||||
| Acquisitions | 2 | — | — | — | 2 | ||||||||||||||||||||||||
| Assets in Redevelopment | — | (1) | — | — | (1) | ||||||||||||||||||||||||
| Prior Development/Redevelopment | 1 | 1 | — | — | 2 | ||||||||||||||||||||||||
| Significant tenant relocation | — | (1) | — | — | (1) | ||||||||||||||||||||||||
| Assets sold | (59) | — | — | — | (59) | ||||||||||||||||||||||||
| Current Quarter Three-Month SS Property Count | 513 | 111 | 15 | — | 639 | ||||||||||||||||||||||||
| 24 | ||||
| Reconciliations | ||
| Common Stock and Equivalents | ||
| Weighted Average Shares | Weighted Average Shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares Outstanding September 30, 2024 | Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | Diluted EPS | Diluted Nareit FFO | Diluted FFO as Adjusted | Diluted AFFO | |||||||||||||||||||||||||||||||||||||||||||||
| Common stock | 699,405 | 699,349 | 699,349 | 699,349 | 699,349 | 667,536 | 667,536 | 667,536 | 667,536 | ||||||||||||||||||||||||||||||||||||||||||||
Common stock equivalent securities(1): | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restricted stock units | 963 | 137 | 137 | 137 | 137 | 150 | 150 | 150 | 150 | ||||||||||||||||||||||||||||||||||||||||||||
| OP units | 3,177 | 660 | 1,606 | 1,606 | 1,606 | 410 | 1,190 | 1,190 | 1,190 | ||||||||||||||||||||||||||||||||||||||||||||
| Convertible partnership units | 13,558 | — | 13,623 | 13,623 | 13,623 | — | 12,252 | 12,252 | 12,252 | ||||||||||||||||||||||||||||||||||||||||||||
| Total common stock and equivalents | 717,103 | 700,146 | 714,715 | 714,715 | 714,715 | 668,096 | 681,128 | 681,128 | 681,128 | ||||||||||||||||||||||||||||||||||||||||||||
______________________________________
(1)The weighted average shares for the three months ended September 30, 2024 represent the current dilutive impact, using the treasury stock method, of approximately 1.0 million restricted stock units, 3.2 million OP Units, and 13.6 million DownREIT units.
| 25 | ||||
| Reconciliations | ||
| Net Income to Adjusted EBITDAre | ||
In thousands
| Three Months Ended September 30, 2024 | |||||
| Net income (loss) | $ | 92,738 | |||
| Interest expense | 74,105 | ||||
| Income tax expense (benefit) | 1,938 | ||||
| Depreciation and amortization | 280,019 | ||||
| Other depreciation and amortization | 807 | ||||
| Loss (gain) on sales of real estate | (62,325) | ||||
| Loss (gain) upon change of control | 430 | ||||
| Share of unconsolidated JV: | |||||
| Interest expense | 5,859 | ||||
| Income tax expense (benefit) | 24 | ||||
| Depreciation and amortization | 12,127 | ||||
| EBITDAre | $ | 405,722 | |||
| Transaction and merger-related items | 2,743 | ||||
| Other impairments (recoveries) and other losses (gains) | 441 | ||||
| Casualty-related charges (recoveries) | 2,074 | ||||
| Stock-based compensation amortization expense | 3,755 | ||||
Impact of transactions closed during the period(1) | (598) | ||||
| Adjusted EBITDAre | $ | 414,137 | |||
Impact of transactions closed during the period(1) | 598 | ||||
Fixed Charge Coverage Adjusted EBITDAre(2) | $ | 414,735 | |||
| Adjusted Fixed Charge Coverage | ||
In thousands
| Three Months Ended September 30, 2024 | |||||
| Interest expense, including unconsolidated JV interest expense at share | $ | 79,964 | |||
| Capitalized interest, including unconsolidated JV capitalized interest at share | 16,681 | ||||
| Fixed Charges | $ | 96,645 | |||
| Adjusted Fixed Charge Coverage | 4.3x | ||||
______________________________________
(1)Adjustment reflects the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period.
(2)Fixed Charge Coverage Adjusted EBITDAre is utilized in the calculation of Adjusted Fixed Charge Coverage and excludes the impact of transactions that closed during the period for consistency with the calculation of Fixed Charges.
| 26 | ||||
| Reconciliations | ||
| Enterprise Debt and Net Debt | ||
In thousands
| 2024年9月30日 | |||||
| 期限貸款 | $ | 1,645,748 | |||
| 高級無擔保票據 | 6,557,170 | ||||
| 抵押債務 | 380,459 | ||||
| 合併債務 | $ | 8,583,377 | |||
| 非合併企業債務股份 | 186,356 | ||||
| 企業債務 | $ | 8,769,733 | |||
| 現金及現金等價物 | (180,430) | ||||
| 未納入合併的合營企業現金及現金等價物份額 | (30,851) | ||||
| 受限現金 | (61,615) | ||||
| 未納入合併的合營企業受限現金份額 | (5,357) | ||||
| 淨債務 | $ | 8,491,480 | |||
| 財務槓桿 | ||
以千爲單位
| 2024年9月30日 | |||||
| 企業債務 | $ | 8,769,733 | |||
| 企業總資產 | 24,934,139 | ||||
| 財務槓桿 | 35.2% | ||||
| 擔保債務比率 | ||
以千爲單位
| 2024年9月30日 | |||||
| 抵押債務 | $ | 380,459 | |||
| 未納入合併範圍的JV按揭債務份額 | 186,356 | ||||
| 企業擔保債務 | $ | 566,815 | |||
| 企業總資產 | $ | 24,934,139 | |||
| 擔保債務比率 | 2.3% | ||||
| 淨負債與調整後的EBITDAre比率 | ||
以千爲單位
| 2024年9月30日 | |||||
| 淨債務 | $ | 8,491,480 | |||
年化調整後的EBITDAre(1) | 1,656,548 | ||||
| 淨債務與調整後的EBITDAre比率 | 5.1倍 | ||||
______________________________________
(1)代表當前季度的調整後的息稅折舊及攤銷前利潤乘以四倍。
| 27 | ||||
| 協調 | ||
| Healthpeak的非合併合資企業淨營業收入份額 | ||
以千爲單位
| 總投資組合 | 三個月已結束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 來自未合併合資企業的股權收益（虧損） | $ | 2,101 | $ | 3,558 | $ | 2,376 | $ | 51 | $ | (3,834) | |||||||||||||||||||
| 折舊和攤銷 | 6,190 | 6,724 | 8,772 | 11,621 | 12,127 | ||||||||||||||||||||||||
| 一般和行政 | 267 | 199 | 337 | 79 | 353 | ||||||||||||||||||||||||
| 其他（收入）支出，淨額 | (1,558) | (2,389) | (1,005) | 883 | 4,670 | ||||||||||||||||||||||||
| 所得稅（福利）支出 | 45 | 203 | 147 | 166 | 8 | ||||||||||||||||||||||||
| Healthpeak 在未合併合資企業 NOI 中的份額 | $ | 7,045 | $ | 8,295 | $ | 10,627 | $ | 12,800 | $ | 13,324 | |||||||||||||||||||
| 門診醫療 | 三個月已結束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 來自未合併合資企業的股權收益（虧損） | $ | 211 | $ | 251 | $ | (1,110) | $ | (2,922) | $ | (5,185) | |||||||||||||||||||
| 折舊和攤銷 | 218 | 241 | 1,615 | 4,270 | 4,253 | ||||||||||||||||||||||||
| 一般和行政 | 15 | (3) | 44 | 133 | 91 | ||||||||||||||||||||||||
| 其他（收入）支出，淨額 | — | — | 1,099 | 2,965 | 5,082 | ||||||||||||||||||||||||
| 所得稅（福利）支出 | 1 | 4 | 8 | (7) | (8) | ||||||||||||||||||||||||
| Healthpeak 在未合併合資企業 NOI 中的份額 | $ | 445 | $ | 493 | $ | 1,656 | $ | 4,439 | $ | 4,233 | |||||||||||||||||||
| 實驗室 | 三個月已結束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 來自未合併合資企業的股權收益（虧損） | $ | 1,244 | $ | 1,384 | $ | 2,811 | $ | 2,247 | $ | 1,754 | |||||||||||||||||||
| 折舊和攤銷 | 1,568 | 1,992 | 2,573 | 2,693 | 3,194 | ||||||||||||||||||||||||
| 一般和行政 | 220 | 134 | 217 | (53) | 242 | ||||||||||||||||||||||||
| 其他（收入）支出，淨額 | (1,565) | (1,208) | (2,064) | (2,114) | (1,759) | ||||||||||||||||||||||||
| Healthpeak 在未合併合資企業 NOI 中的份額 | $ | 1,467 | $ | 2,302 | $ | 3,537 | $ | 2,773 | $ | 3,431 | |||||||||||||||||||
| 其他 | 三個月之內結束 | ||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | |||||||||||||||||||||||||
| 與未納入合併範圍的合資企業的股權收益（損失） | $ | 646 | $ | 1,923 | $ | 675 | $ | 726 | $ | (403) | |||||||||||||||||||
| 折舊和攤銷 | 4,404 | 4,491 | 4,584 | 4,658 | 4,680 | ||||||||||||||||||||||||
| ZSCALER, INC. | 32 | 68 | 76 | (1) | 20 | ||||||||||||||||||||||||
| 其他（收入）支出，淨額 | 7 | (1,181) | (40) | 32 | 1,347 | ||||||||||||||||||||||||
| 所得稅（收益）費用 | 44 | 199 | 139 | 173 | 16 | ||||||||||||||||||||||||
| Healthpeak在未納入合併範圍的合資企業的分擔淨運營收入 | $ | 5,133 | $ | 5,500 | $ | 5,434 | $ | 5,588 | $ | 5,660 | |||||||||||||||||||
| 28 | ||||
| 協調 | ||
| Healthpeak的非合併合資企業淨營業收入份額 | ||
以千爲單位
截至2024年9月30日止九個月
| 門診 醫療 | 實驗室 | 其他 | 總費用 | |||||||||||||||||||||||
| 來自未納入合併報表的合營公司的股權收入（虧損） | $ | (9,217) | $ | 6,812 | $ | 998 | $ | (1,407) | ||||||||||||||||||
| 折舊和攤銷 | 10,138 | 8,460 | 13,922 | 32,520 | ||||||||||||||||||||||
| ZSCALER, INC. | 267 | 406 | 95 | 768 | ||||||||||||||||||||||
| 其他（收入）支出，淨額 | 9,146 | (5,937) | 1,338 | 4,547 | ||||||||||||||||||||||
| 所得稅（收益）費用 | (7) | — | 328 | 321 | ||||||||||||||||||||||
| Healthpeak在未納入合併範圍的合資企業的分擔淨運營收入 | $ | 10,327 | $ | 9,741 | $ | 16,681 | $ | 36,749 | ||||||||||||||||||
2023年9月30日結束的九個月內的合同餘額
| 門診 醫療 | 實驗室 | 其他 | 總費用 | |||||||||||||||||||||||
| 與未納入合併範圍的合資企業的股權收益（損失） | $ | 585 | $ | 3,155 | $ | 2,906 | $ | 6,646 | ||||||||||||||||||
| 折舊和攤銷 | 712 | 4,504 | 12,860 | 18,076 | ||||||||||||||||||||||
| ZSCALER, INC. | 41 | 774 | 143 | 958 | ||||||||||||||||||||||
| 其他（收入）支出，淨額 | — | (4,901) | (47) | (4,948) | ||||||||||||||||||||||
| 所得稅（收益）費用 | 12 | — | 484 | 496 | ||||||||||||||||||||||
| Healthpeak在未納入合併範圍的合資企業的分擔淨運營收入 | $ | 1,350 | $ | 3,532 | $ | 16,346 | $ | 21,228 | ||||||||||||||||||
| 29 | ||||
| 協調 | ||
| 非控股權益在合併的合資創業公司中的淨營業收入份額 | ||
以千爲單位
| 總投資組合 | 三個月已結束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 歸因於非控股權益的持續經營收入（虧損） | $ | 4,442 | $ | 4,451 | $ | 4,501 | $ | 6,669 | $ | 6,866 | |||||||||||||||||||
| 折舊和攤銷 | 4,474 | 4,502 | 4,452 | 4,614 | 4,415 | ||||||||||||||||||||||||
| 其他（收入）支出，淨額 | 6 | 23 | 124 | 84 | 207 | ||||||||||||||||||||||||
| 歸屬於非控股權益的股息 | (2,540) | (2,586) | (2,511) | (4,611) | (4,605) | ||||||||||||||||||||||||
| 非控股權益在合併合資企業NOI中的份額 | $ | 6,382 | $ | 6,390 | $ | 6,566 | $ | 6,756 | $ | 6,883 | |||||||||||||||||||
| 門診醫療 | 三個月已結束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 歸因於非控股權益的持續經營收入（虧損） | $ | 3,181 | $ | 3,162 | $ | 3,266 | $ | 5,398 | $ | 5,661 | |||||||||||||||||||
| 折舊和攤銷 | 4,422 | 4,452 | 4,402 | 4,603 | 4,415 | ||||||||||||||||||||||||
| 其他（收入）支出，淨額 | 97 | 117 | 215 | 107 | 177 | ||||||||||||||||||||||||
| 歸屬於非控股權益的股息 | (1,439) | (1,464) | (1,437) | (3,376) | (3,370) | ||||||||||||||||||||||||
| 非控股權益在合併合資企業NOI中的份額 | $ | 6,261 | $ | 6,267 | $ | 6,446 | $ | 6,732 | $ | 6,883 | |||||||||||||||||||
| 實驗室 | 三個月已結束 | ||||||||||||||||||||||||||||
| 9月30日 2023 | 十二月 31, 2023 | 三月三十一日 2024 | 6月30日 2024 | 九月三十日 2024 | |||||||||||||||||||||||||
| 歸因於非控股權益的持續經營收入（虧損） | $ | 1,061 | $ | 1,093 | $ | 1,044 | $ | 949 | $ | 883 | |||||||||||||||||||
| 折舊和攤銷 | 52 | 50 | 50 | 11 | — | ||||||||||||||||||||||||
| 其他（收入）支出，淨額 | (91) | (94) | (91) | (23) | 30 | ||||||||||||||||||||||||
| 歸屬於非控股權益的股息 | (901) | (926) | (883) | (913) | (913) | ||||||||||||||||||||||||
| 非控股權益在合併合資企業NOI中的份額 | $ | 121 | $ | 123 | $ | 120 | $ | 24 | $ | — | |||||||||||||||||||
| 企業非區段 | 三個月之內結束 | ||||||||||||||||||||||||||||
| 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | |||||||||||||||||||||||||
| 持續經營業務可歸屬於非控制權益的損益 | $ | 200 | $ | 196 | $ | 191 | $ | 322 | $ | 322 | |||||||||||||||||||
| 歸屬於非控股權益的分紅派息 | (200) | (196) | (191) | (322) | (322) | ||||||||||||||||||||||||
| 非控制利益在合併範圍內的合資企業淨運營收入中的份額 | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||
| 30 | ||||
| 協調 | ||
| 非控股權益在合併的合資創業公司中的淨營業收入份額 | ||
以千爲單位
截至2024年9月30日止九個月
| 門診 醫療 | 實驗室 | 企業 非分段 | 總計 | |||||||||||||||||||||||
| 歸因於非控股權益的持續經營收入（虧損） | $ | 14,325 | $ | 2,876 | $ | 835 | $ | 18,036 | ||||||||||||||||||
| 折舊和攤銷 | 13,420 | 61 | — | 13,481 | ||||||||||||||||||||||
| 其他（收入）支出，淨額 | 501 | (84) | — | 417 | ||||||||||||||||||||||
| 歸屬於非控股權益的股息 | (8,183) | (2,709) | (835) | (11,727) | ||||||||||||||||||||||
| 非控股權益在合併合資企業NOI中的份額 | $ | 20,063 | $ | 144 | $ | — | $ | 20,207 | ||||||||||||||||||
2023年9月30日結束的九個月內的合同餘額
| 門診 醫療 | 實驗室 | 公司 非分段 | 總費用 | |||||||||||||||||||||||
| 持續經營業務可歸屬於非控制權益的損益 | $ | 20,285 | $ | 3,622 | $ | 390 | $ | 24,297 | ||||||||||||||||||
| 房地產業銷售淨收益（損失） | (11,133) | (413) | — | (11,546) | ||||||||||||||||||||||
| 折舊和攤銷 | 13,617 | 141 | — | 13,758 | ||||||||||||||||||||||
| 其他（收入）支出，淨額 | 438 | (277) | — | 161 | ||||||||||||||||||||||
| 歸屬於非控股權益的分紅派息 | (4,320) | (2,732) | (390) | (7,442) | ||||||||||||||||||||||
| 非控制權益在合併創業公司淨營業收入中的份額 | $ | 18,887 | $ | 341 | $ | — | $ | 19,228 | ||||||||||||||||||
| 31 | ||||
| 協調 | ||
REVOR CCRC(1) | ||
以千爲單位，除每月數據外
| 三個月之內結束 | |||||||||||||||||||||||||||||
| REVPOR CCRC | 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||
投資組合現金房地產營業收入(2) | $ | 133,808 | $ | 136,340 | $ | 138,777 | $ | 140,890 | $ | 142,845 | |||||||||||||||||||
CCRC的其他調整(3) | (206) | — | — | — | — | ||||||||||||||||||||||||
| CCRC營收 | $ | 133,603 | $ | 136,340 | $ | 138,777 | $ | 140,890 | $ | 142,845 | |||||||||||||||||||
| 每月平均入住單位 | 5,956 | 6,031 | 6,043 | 6,049 | 6,013 | ||||||||||||||||||||||||
每月CCRC每單位收入(4) | $ | 7,477 | $ | 7,536 | $ | 7,655 | $ | 7,764 | $ | 7,919 | |||||||||||||||||||
| 三個月之內結束 | |||||||||||||||||||||||||||||
| 不包括NREF攤銷的REVPOR CCRC | 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||
| REVPOR CCRC營收 | $ | 133,603 | $ | 136,340 | $ | 138,777 | $ | 140,890 | $ | 142,845 | |||||||||||||||||||
| 非現金化攤銷 | (20,762) | (22,105) | (21,577) | (21,401) | (22,622) | ||||||||||||||||||||||||
| REVPOR長期照護產生的收入，不包括非現金化攤銷 | $ | 112,841 | $ | 114,235 | $ | 117,200 | $ | 119,489 | $ | 120,223 | |||||||||||||||||||
| 每月平均入住單位數 | 5,956 | 6,031 | 6,043 | 6,049 | 6,013 | ||||||||||||||||||||||||
REVPOR長期照護產生的收入，每月不包括非現金化攤銷(4) | $ | 6,315 | $ | 6,314 | $ | 6,465 | $ | 6,585 | $ | 6,665 | |||||||||||||||||||
_____________________________________
(1)可能不準確，因爲四捨五入。
(2)查看本文檔的第13頁和第14頁，了解投資組合現金房地產收入的調解情況.
(3)包括2023年9月30日結束的三個月內尚未穩定的改建中或最近完成的設施的營業收入。
(4)代表每間客房每半天收入（REVPOR）除以三的比例。
| 32 | ||||
| 協調 | ||
REVPOR(1) | ||
以千爲單位，除每月數據外
| 三個月之內結束 | |||||||||||||||||||||||||||||
| 其他REVPOR | 截至2023年9月30日年
度報告 2023 | 截至12月31日公允價值 2023 | 3月31日 2024 | 6月30日, 2024 | 2020年9月30日 2024 | ||||||||||||||||||||||||
投資組合現金房地產營業收入(2) | $ | 20,567 | $ | 21,167 | $ | 21,477 | $ | 21,360 | $ | 21,815 | |||||||||||||||||||
對REVPOR的其他調整(3) | (2,456) | — | — | — | — | ||||||||||||||||||||||||
| REVPOR收入 | $ | 18,111 | $ | 21,167 | $ | 21,477 | $ | 21,360 | $ | 21,815 | |||||||||||||||||||
| 每月平均入住單位數 | 1,320 | 1,410 | 1,401 | 1,415 | 1,450 | ||||||||||||||||||||||||
每月REVPOR(4) | $ | 4,573 | $ | 5,005 | $ | 5,109 | $ | 5,032 | $ | 5,016 | |||||||||||||||||||
______________________________________
(1)可能不準確，因爲四捨五入。
(2)請查看本文檔第13頁和第14頁，了解投資組合現金房地產收入的調解。
(3)包括2023年9月30日結束的三個月中尚未穩定的資產再開發或最近完成的再開發的收入。
(4)表示季度REVPOR除以三的倍數。
| 33 | ||||
前瞻性聲明
非依據通用證券訴訟改革法案，非依據歷史事實的所有聲明均屬於「前瞻性聲明」。這些前瞻性聲明可能包含我們目前預期、估計和對我們的管理人員所做假設的行業和市場以及我方所在地區的信仰，涉及可能嚴重影響我們的財務或經營結果的不確定性。諸如「預期」、「預測」、「意圖」、「計劃」、「相信」、「尋求」、「估計」、「預測」、「計劃」、「預測」、「將會」、「可能」的詞語，以及這些詞語和類似表達的變體，旨在識別此類前瞻性聲明。此類前瞻性聲明包括關於我們的業務展望、2024年的指引、未來收購、處置、發展、融資活動、租賃活動、財務和經營結果、計劃、目標、預期和意圖的聲明
| 34 | ||||